Loading
A phase 3 trial of Gedatolisib, Palbociclib, Fulvestrant and Alpelisib in advanced solid tumours, run by Celcuity Inc, active and no longer recruiting.
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) is a phase 3 interventional study registered as NCT05501886 by Celcuity Inc, with 701 participants enrolled, started 2022-12-08 and due to reach its primary completion in 2026-06-30. Interventions recorded: Gedatolisib, Palbociclib, Fulvestrant and Alpelisib.
Shares Celcuity, Gedatolisib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Alpelisib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alpelisib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Palbociclib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Palbociclib, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.